A5069198031- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Cutaneous lymphoproliferative disorders research
- Colorectal Cancer Treatments and Studies
- Aortic aneurysm repair treatments
- Aortic Disease and Treatment Approaches
- Cardiac Valve Diseases and Treatments
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-related skin toxicity
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Autoimmune Bullous Skin Diseases
- Cancer and Skin Lesions
- Dermatologic Treatments and Research
- Polyomavirus and related diseases
- Nail Diseases and Treatments
- Infections and bacterial resistance
- Inflammatory Myopathies and Dermatomyositis
- Surgical Sutures and Adhesives
- T-cell and Retrovirus Studies
- Connective tissue disorders research
- Dermatological and Skeletal Disorders
- Pesticide Exposure and Toxicity
- Bone fractures and treatments
Stanford Medicine
2017-2025
Palo Alto University
2018-2025
Stanford University
2015-2024
University of California, San Diego
2022
Johns Hopkins University
2012
Physical Sciences (United States)
2012
Mogamulizumab is a monoclonal antibody against CCR4 approved for treatment mycosis fungoides (MF) and Sézary syndrome (SS). Mogamulizumab-associated rash (MAR) difficult to differentiate from cutaneous MF or SS, which can lead unnecessary discontinuation of drug use because concern severe reaction incorrect presumption disease relapse progression in the skin.To examine most common clinical presentations MAR patients with SS diagnostic management challenges.This retrospective case series...
Rash is one of the most common adverse events observed with mogamulizumab, an anti-C-C chemokine receptor 4 monoclonal antibody approved for previously treated mycosis fungoides (MF) and Sezary syndrome (SS). Given nonspecific clinical presentations this rash, histopathologic distinction from MF/SS critical informing management. We performed a comprehensive characterization findings in mogamulizumab-associated rash (MAR) integration high-throughput sequencing T-cell (TCR) genes. Fifty-two...
Importance Cutaneous squamous cell carcinoma (CSCC) risk stratification is central to management, and physicians rely on tumor staging systems estimate risk. The Brigham Women’s Hospital (BWH) T system predicts based 4 factors (RFs). However, stage not precisely associated with the number of RFs, as BWH T2b includes CSCCs 2 3 RFs. Objective To determine how RF recurrence, metastasis, disease-related death. Design, Setting, Participants This retrospective multination cohort study diagnosed...
"CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients Cutaneous Squamous Cell Carcinoma Risk Stratified According to National Comprehensive Cancer Network Guidelines" published on 28 Mar 2025 by Network.
Immunotherapy with immune checkpoint inhibitors that target the programmed cell-death receptor 1 (PD-1) is increasingly used for patients advanced or metastatic melanoma, non–small cell lung cancer, renal carcinoma, Hodgkin lymphoma, and urothelial carcinoma. Cutaneous adverse events occur during treatment these agents include pruritus, vitiligo, lichenoid dermatitis, psoriasiform and, more recently, bullous pemphigoid other autoimmune blistering disease.1-8 Interestingly, radiation therapy...
PURPOSE To evaluate the feasibility of administering three doses neoadjuvant atezolizumab before curative surgical resection in patients with advanced cutaneous squamous cell carcinoma (cSCC). PATIENTS AND METHODS This single-arm phase II trial included cSCC head and neck stage III or IV disease, lesions for which standard therapy would incur an unacceptable morbidity. Patients received up to at a fixed dose 1,200 mg every 21 days undergoing resection. The primary end point was percentage...
Objective: To utilize 3-D modeling techniques to better characterize geometric deformations of the supra-aortic arch branch vessels and descending thoracic aorta after endovascular aortic repair. Methods: Eighteen patients underwent repair either type B dissection (n = 10) or aneurysm 8). Computed tomography angiography was obtained pre- postprocedure, models were constructed. Branch angle curvature metrics ascending aorta, arch, stented lumen calculated both at postintervention. Results:...
Five hundred ten women identified as SMW (lesbian [20.4%], bisexual [66.9%], something else [12.7%]) and 6378 heterosexual (response rate to SPB questionnaire: 92.3% [6359/6888]).Compared women, were less likely use sunscreen (aOR 0.77, 95% CI 0.61-0.99),but reported similar long-sleeve clothing shade-seeking.SMW spent more time outdoors on workdays (difference 29.1 minutes, 19.4-38.9)and nonworkdays 24.7 13.8-35.6).SMW also had an increased odds of spending at least 3 hours during 1.95,...
Merkel cell carcinoma (MCC) is a rare aggressive cutaneous neuroendocrine tumor with high risk of locoregional recurrence and distant metastasis. Immune checkpoint inhibitors (ICIs), avelumab pembrolizumab, have been approved by the US Food Drug Administration for treatment advanced MCC.1